Adachi and co-workers identified a role for other receptor tyrosine kinases such as EGFR, PDGFRα (platelet-derived growth factor receptor α), and IGFR (insulin-like growth factor receptor) in the emergence of resistance to FGFR inhibitor treatment in FGFR1-amplified lung cancer [236]. The gene discussed is EGFR; the disease is lung carcinoma.